Medication Therapy ManagementPHARMOGNCT04151797
Impact of a Mobile Geriatric Team With a Pharmacist on the Optimisation of Prescriptions in Elderly Inpatients
A study testing Medication therapy management in people with Medication Therapy Management, run by University Hospital, Toulouse at 1 site in France.
Trial summary
In patients aged 75 years and older, polypathology is frequent and often associated with polypharmacy. This polypharmacy coupled with a lack of proactive elderly care can sometimes lead to hospitalisation. Read more about this study
- Who is it for?
- Ages 75 years and older
- Conditions the study is for
- Medication Therapy Management
- What is being tested?
- Medication therapy management
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteFrance
- Study dates
- 19 Nov 2019to 22 Mar 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 75 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Patient aged 75 or older
- Having 5 medications or more per day
- Being hospitalised either in emergency room, short-stay medicine unit or surgery department
Who cannot join
- Patient refuses to participate
- Patient already included in another study
Trial locations and contacts
1 site in 1 country.
About this study
In patients aged 75 years and older, polypathology is frequent and often associated with polypharmacy. This polypharmacy coupled with a lack of proactive elderly care can sometimes lead to hospitalisation. Due to comorbidities and complex problems, management of geriatric patients usually requires a multidisciplinary approach. In Toulouse University Hospital, elderly inpatients can benefit from a geriatric assessment by a Geriatric Mobile Team. Whether this team improve the prescriptions through the advice of a clinical pharmacist has not been demonstrated yet.
Read the detailed description
All participants will be identified via the geriatrician of the mobile geriatric team with the following inclusion criteria: age ≥ 75 years, ≥ 5 medications per day and being hospitalised either in emergency room, short-stay medicine unit or in a surgery department. For each patient, the pharmacist will detect potentially inappropriate prescribing (based on explicit criteria and an implicit approach) and liaise with the geriatrician for drug optimisations. The pharmaceutical advice will be added to the geriatrician's written report, and then addressed to the relevant physician. The implementation of the proposals will be evaluated immediately at the end of hospitalisation, and then reassessed three months later by calling the patient and/or his community pharmacist. A total of 250 patients will be enrolled over a 12 month-period. The evolution of potentially inappropriate prescribing will be assessed and their cost evaluated.
- Conditions
- Medication Therapy Management
- Being tested
- Medication therapy management
- Keywords
- Medication review, clinical pharmacy, polypharmacy, older people, collaboration, inappropriate prescribing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Medication therapy managementOther
The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:
- Data collection on comorbidities, medication and laboratory results.
- A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.
- A detailed feedback to the geriatrician.
- A written report addressed to the attending physician
| Study group | Role | What they receive |
|---|---|---|
| Medication therapy management | Experimental | Medication therapy management by pharmacist-led medication review Receives: Other: Medication therapy management |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline patients' number of potentially inappropriate prescription at the patient discharge after optimization by a mobile geriatric team with pharmacist
number of potentially inappropriate prescribing per patient before (month 0) and after the intervention of the mobile geriatric team (at the patient discharge)
Measured: Month 0 and max Month 2 (At the patient discharge)
Secondary outcomes (9)
Change from baseline patients' number of potentially inappropriate prescription at 3 months after optimization by a mobile geriatric team with pharmacist
number of potentially inappropriate prescribing per patient before (month 0) and after the intervention of the mobile geriatric team (month 3)
Measured: Month 0, Month 3
Change from baseline patients' number with at least one potentially inappropriate drug at 3 months after optimization by a mobile geriatric team with pharmacist
number of patients with at least one potentially inappropriate drug before (month 0) and after the intervention of the mobile geriatric team (month 3)
Measured: Month 0, Month 3
Change from baseline ratio of potentially inappropriate drug per patient at 3 months after optimization by a mobile geriatric team with pharmacist
ratio of potentially inappropriate drug per patient before (month 0) and after (month 3) the intervention of the mobile geriatric team.
Measured: Month 0, Month 3
Change from baseline mean number of medications per patient at 3 months
Mean number of medications per patient
Measured: Month 0, Month 3
realisation of a pharmacist-led medication review in primary care
Number of pharmacist-led medication review performed in primary care at 3 months
Measured: Month 3
number of falls 3 months after pharmacist-led medication review
Number of falls
Measured: Month 3
mortality 3 months after pharmacist-led medication review
Number of deaths
Measured: Month 3
re-hospitalisation, including emergency room transfers
Number of non-scheduled hospitalisations (including emergency department transfers)
Measured: Month 3
The nursing home transfers
Number of nursing home transfers
Measured: Month 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2019
- Study start19 Nov 2019
- Primary completion22 Mar 2021
- Study completion22 Mar 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Medication Therapy ManagementStudies of the same condition, open and under way.
- More trials run by University Hospital, ToulouseThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Toulouse
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Philippe CESTAC, PharmD, PhD, Principal investigator, University Hospital, Toulouse
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04151797
- Sponsor's protocol ID
- RC31/17/0353
- Acronym
- PHARMOG
- Status last verified
- May 2021
- First submitted
- 15 Oct 2019
- Last updated
- 28 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Pages A, Roland C, Qassemi S, Abdeljalil AB, Houles M, Romain M, Toulza O, Belloc A, McCambridge C, Voisin T, Cestac P, Juillard-Condat B; PharMoG study group. Impact of a Pharmacist-included Mobile Geriatrics team intervention on potentially inappropriate drug prescribing: protocol for a prospective feasibility study (PharMoG study). BMJ Open. 2020 Dec 2;10(12):e040917. doi: 10.1136/bmjopen-2020-040917.
PubMed 33268421Dintilhac A, Qassemi S, Roland C, McCambridge C, Abdeljalil AB, Houles M, Romain M, Toulza O, Dunet C, Belloc A, Strumia M, Cestac P, Voisin T, Juillard-Condat B. The impact of an intervention by a mobile geriatrics team including a pharmacist on potentially inappropriate drug prescription: results of the PharMoG study. BMC Geriatr. 2026 Mar 21;26(1):598. doi: 10.1186/s12877-026-07366-1.
PubMed 41862799
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of a Mobile Geriatric Team With a Pharmacist on the Optimisation of Prescriptions in Elderly Inpatients
- ClinicalTrials.gov ID
- NCT04151797
- Acronym / sponsor ID
- PHARMOG / RC31/17/0353
- Conditions
- Medication Therapy Management
- Keywords
- Medication review, clinical pharmacy, polypharmacy, older people, collaboration, inappropriate prescribing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- University Hospital, ToulouseUniversity, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France
- Study start
- 19 Nov 2019 (actual)
- Primary completion
- 22 Mar 2021 (actual)
- Study completion
- 22 Mar 2021 (actual)
- First posted
- 5 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In patients aged 75 years and older, polypathology is frequent and often associated with polypharmacy. This polypharmacy coupled with a lack of proactive elderly care can sometimes lead to hospitalisation. Due to comorbidities and complex problems, management of geriatric patients usually requires a multidisciplinary approach. In Toulouse University Hospital, elderly inpatients can benefit from a geriatric assessment by a Geriatric Mobile Team. Whether this team improve the prescriptions through the advice of a clinical pharmacist has not been demonstrated yet.
Detailed description
All participants will be identified via the geriatrician of the mobile geriatric team with the following inclusion criteria: age ≥ 75 years, ≥ 5 medications per day and being hospitalised either in emergency room, short-stay medicine unit or in a surgery department. For each patient, the pharmacist will detect potentially inappropriate prescribing (based on explicit criteria and an implicit approach) and liaise with the geriatrician for drug optimisations. The pharmaceutical advice will be added to the geriatrician's written report, and then addressed to the relevant physician. The implementation of the proposals will be evaluated immediately at the end of hospitalisation, and then reassessed three months later by calling the patient and/or his community pharmacist. A total of 250 patients will be enrolled over a 12 month-period. The evolution of potentially inappropriate prescribing will be assessed and their cost evaluated.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Medication therapy management | Experimental | Other: Medication therapy managementMedication therapy management by pharmacist-led medication review |
Who may qualify
- Ages
- 75 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (3 listed)
- Patient aged 75 or older
- Having 5 medications or more per day
- Being hospitalised either in emergency room, short-stay medicine unit or surgery department
Key exclusion criteria (2 listed)
- Patient refuses to participate
- Patient already included in another study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Medication therapy managementThe intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes: * Data collection on comorbidities, medication and laboratory results. * A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice. * A detailed feedback to the geriatrician. * A written report addressed to the attending physician | Other | Medication therapy management |
Primary outcome
Change from baseline patients' number of potentially inappropriate prescription at the patient discharge after optimization by a mobile geriatric team with pharmacist
Time frame: Month 0 and max Month 2 (At the patient discharge)
number of potentially inappropriate prescribing per patient before (month 0) and after the intervention of the mobile geriatric team (at the patient discharge)
9 secondary outcomes
Change from baseline patients' number of potentially inappropriate prescription at 3 months after optimization by a mobile geriatric team with pharmacist
Time frame: Month 0, Month 3
Change from baseline patients' number with at least one potentially inappropriate drug at 3 months after optimization by a mobile geriatric team with pharmacist
Time frame: Month 0, Month 3
Change from baseline ratio of potentially inappropriate drug per patient at 3 months after optimization by a mobile geriatric team with pharmacist
Time frame: Month 0, Month 3
Change from baseline mean number of medications per patient at 3 months
Time frame: Month 0, Month 3
realisation of a pharmacist-led medication review in primary care
Time frame: Month 3
number of falls 3 months after pharmacist-led medication review
Time frame: Month 3
mortality 3 months after pharmacist-led medication review
Time frame: Month 3
re-hospitalisation, including emergency room transfers
Time frame: Month 3
The nursing home transfers
Time frame: Month 3
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2025.
- Background: PubMed 33268421Pages A, Roland C, Qassemi S, Abdeljalil AB, Houles M, Romain M, Toulza O, Belloc A, McCambridge C, Voisin T, Cestac P, Juillard-Condat B; PharMoG study group. Impact of a Pharmacist-included Mobile Geriatrics team intervention on potentially inappropriate drug prescribing: protocol for a prospective feasibility study (PharMoG study). BMJ Open. 2020 Dec 2;10(12):e040917. doi: 10.1136/bmjopen-2020-040917.
- Derived from this study: PubMed 41862799Dintilhac A, Qassemi S, Roland C, McCambridge C, Abdeljalil AB, Houles M, Romain M, Toulza O, Dunet C, Belloc A, Strumia M, Cestac P, Voisin T, Juillard-Condat B. The impact of an intervention by a mobile geriatrics team including a pharmacist on potentially inappropriate drug prescription: results of the PharMoG study. BMC Geriatr. 2026 Mar 21;26(1):598. doi: 10.1186/s12877-026-07366-1.
- Individual participant dataSharing planned: No
Related trials for Medication Therapy Management
Not yet recruiting
Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition
Hypertension, Diabetes Mellitus, Type 2
Enrolling by invitationPhase 4
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
Complex Regional Pain Syndrome, Chronic Pain
Not yet recruiting
A Nurse-Led Personalized Self-Management Counseling Intervention to Improve Medication Adherence and Glycemic Control in Adults With Type 2 Diabetes: A Randomized Controlled Trial
Medication Adherence, Glycemic Control for Diabetes Mellitus
Not yet recruitingPhase 3
Submucosal Cryotherapy and Anti-inflammatory Drugs for Postoperative Pain Following Root Canal Treatment in Maxillary Molars
Pulpitis
Active, not recruitingObservational study
Investigating the Optimal Management of Dolutegravir Resistance
HIV-1-infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Philippe CESTAC, PharmD, PhD principal investigator
University Hospital, Toulouse
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Medication therapy management in people with Medication Therapy Management, run by University Hospital, Toulouse at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline patients' number of potentially inappropriate prescription at the patient discharge after optimization by a mobile geriatric team with pharmacist (time frame: Month 0 and max Month 2 (At the patient discharge)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04151797, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2025.